Risk from breast cancer susceptibility gene may be exaggerated in most studies

August 20, 2002

An analysis of past studies on mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 suggests that estimates of penetrance (or the likelihood that mutation carriers will develop breast cancer during their lifetime) have been exaggerated. This can happen because a woman's risk of developing breast cancer is likely to be associated not only with the specific genetic mutation but also with many other risk factors, concludes a study in the August 21 issue of the Journal of the National Cancer Institute.

Accurately estimating penetrance is important for genetic counseling because the estimates may influence decisions about cancer prevention, such as whether to undergo a prophylactic mastectomy. Early studies examined families that had multiple cases of breast cancer and resulted very in very high penetrance estimates--in the range of 71% to 85% by 70 years of age.

To avoid this problem, more recent studies have used women with breast cancer who do not necessarily have a strong family history of the disease. These studies have resulted in considerably lower estimates. But this strategy, too, is biased and can still lead to inflated penetrance estimates, according to study author Colin B. Begg, Ph.D., of the Memorial Sloan-Kettering Cancer Center, New York.

He argues that all risk factors for breast cancer are over-represented in incident cases of breast cancer. This means that a sample of women who have been diagnosed with breast cancer who are identified as mutation carriers are more likely to also have other breast cancer risk factors than similar mutation carriers who are disease-free. The current strategy for estimating risk is unbiased only if all carriers share an identical risk of developing the disease, he says.

Begg concludes that, "substantial heterogeneity exists in the risk for cancer among individuals in the population." He points out that the presence of a BRCA mutation in a woman does not completely define her risk for breast cancer because in addition, numerous unknown risk modifiers are likely to exist. He says these modifiers should be reflected in the tools used by genetic counselors to predict risk.

In an accompanying editorial, Wylie Burke, M.D., Ph.D., and Melissa A. Austin, Ph.D., of the University of Washington in Seattle, say the new study underscores the pitfalls of failing to address the complexity of disease risk and its implications for disease prevention. They point out that nongenetic risk factors have been shown to influence the outcome of genetic risk in other settings. For example, they say, smoking, diet, and exercise can modify the effect of genetic risk for heart disease.

"Without a healthy respect for the many factors that may influence penetrance, we will continue to overestimate the risk conferred by BRCA1 and BRCA2 mutations alone and, thus, miss opportunities to develop truly effective prevention strategies for women who are genetically susceptible to breast cancer that are based on a broad understanding of causative factors," they say.
Contact: Christine Hickey, Memorial Sloan-Kettering Cancer Center, (212) 639-3573, fax: (212) 639-3576, publicaffairs@mskcc.org.

Editorial: Walter Neary, University of Washington, Seattle, (206) 685-3841, fax: (206) 685-3333, wneary@u.washington.edu

Begg C. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2002;94:1221-6.

Editorial: Burke W, Austin M. Genetic risk in context: calculating the penetrance of BRCA1 and BRCA2 mutations. J Natl Cancer Inst 2002;94:1185-7.

Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Journal of the National Cancer Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.